Corporate News

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today’s update from Abingdon Health plc (AIM: ABDX) (“Abingdon Health”) regarding the AbC-19^TM Rapid Test, confirming their expectations for future supply arrangements with the Department of Health and Social Care, the ongoing efforts to obtain regulatory approvals in a total of 27 geographies, and the ongoing work to build data the set(s) around the use-case for the AbC-19^TM Rapid Test alongside vaccines.

In addition, Omega will today announce the launch of its COVID-19 antibody lab-based testing service in Littleport, Cambridgeshire (see separate RNS Reach for details), using the Mologic ELISA¹ antibody test. This service will be offered to commercial occupational health partners, clinics and health care professionals in the UK.

Colin King, CEO of Omega Diagnostics, said: “We welcome the update from Abingdon Health this morning and look forward to being able to update investors on the potential to open up significant commercial opportunities outside of the UK in due course.” 

¹ELISA (Enzyme Linked Immuno-Sorbent Assay)

Contacts: